Trinity Biotech plc Overview
Pro stress-test →Trinity Biotech develops, manufactures, and markets clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. The company operates across infectious disease testing (HIV), diabetes management (HbA1c analyzers), and emerging continuous glucose monitoring technology, with recent strong momentum in global HIV testing driven by WHO-approved manufacturing models.
Strategic Profile
Pro stress-test →Trinity Biotech is executing a Comprehensive Transformation Plan with WHO approval for outsourced manufacturing and expects further Adjusted EBITDA improvement. The company's Premier Hb9210 HbA1c Analyser achieved the prestigious IFCC Gold Classification for 2026, making it the only HbA1c system worldwide to earn this certification. The company is advancing next-generation CGM+ continuous glucose monitoring with needle-free sensor technology.
Competitive Landscape
Pro stress-test →Bio-Rad Laboratories, Diasorin, Luminex, and Abbott are competitors of Trinity Biotech. Trinity differentiates through point-of-care diagnostic products, WHO-prequalified HIV tests with manufacturing cost advantages, and FDA-cleared diabetes monitoring technology recognized for superior accuracy certification.
Industry Context
Trinity Biotech plc operates in Clinical Diagnostics & Medical Devices.
Key facts
Founded: 1992 · Headquarters: Bray, Ireland · Revenue: $48.6M